Cryotherapy for Primary Treatment of Prostate Cancer: Intermediate Term Results of a Prospective Study from a Single Institution

Table 3

Log Rank test comparative risk.

(a)

Risk					Average
			Censored				95% CI
	Total number	Events	𝑁	Percentage	Estimate	Typical error	Lower limit	Upper limit
Low	28	1	27	96.4%	120,926	3,988	113,090	128,762
Intermediate	34	3	31	91.2%	112,643	6,742	99,429	125,857
High	45	17	28	62.2%	79,554	8,413	6,065	96,044
Gleason
5 (3+2)	1	0	1	100.0%	—	—	—	—
6 (3+3)	54	4	50	92.6%	119,321	5,418	108,702	129,939
7 (3+4)	19	3	16	84.2%	112,217	10,434	91,767	132,666
7 (4+3)	17	5	12	70.6%	90,500	14,373	62,329	118,671
8 (4+4)	14	7	7	50.0%	45,093	9,799	25,886	64,299
9 (4+5)	2	2	0	0%	—	—	—	—
Global	107	21	86	86.4%	100,254	4,769	90,908	109,600

(b)

Pairs comparison
	Risk	1		2		3
		Chi-square	Sig.	Chi-square	Sig.	Chi-square	Sig.
Log Rank; (Mantel-Cox)	Low			.927	.336	10,337	.001
	Intermediate	.927	.336			6,730	.009
	High	10,337	.001	6,730	.009